Alzamend Neuro is trading at $1.43, up 9.13%, with no new company announcement or clearly reported catalyst identified for October 13.
- The company’s latest press-release listing shows September 16 as its newest release.
- A Zacks Rank #2 (Buy) upgrade published October 8 cited rising earnings estimates, but available reporting does not link it directly to the move.
- Major-index context is mixed and does not establish a broad-market explanation for the gain.